Predicting response to rFVIIa in neonates with intractable bleeding or severe coagulation disturbances.

Background: To date, clinical experience with recombinant factor VIIa (rFVIIa) in neonates is rather limited because of the lack of controlled studies. ΑIM: The objective of this study was to present further experience from our center with regard to the use of rFVIIa in newborns with severe bleeding or coagulopathy resistant to conventional therapy and to determine factors affecting the clinical outcome.

Methodology: We performed a retrospective data analysis of 29 neonates with intractable bleeding or severe coagulation disturbances.